Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Blasco-Blanco, M. (Manuel) | - |
dc.creator | Martinez, P. (Patricia) | - |
dc.creator | Baixauli-Fons, J. (Jorge) | - |
dc.creator | Pastor, C. (Carlos) | - |
dc.creator | Rodriguez, J. (Javier) | - |
dc.creator | Pardo, F. (Fernando) | - |
dc.creator | Rotellar, F. (Fernando) | - |
dc.creator | Chopitea, A. (Ana) | - |
dc.creator | Hernandez-Lizoain, J.L. (Jose Luis) | - |
dc.date.accessioned | 2014-08-30T17:05:20Z | - |
dc.date.available | 2014-08-30T17:05:20Z | - |
dc.date.issued | 2014-04 | - |
dc.identifier.citation | Arredondo J, Martínez P, Baixauli J, Pastor C, Rodríguez J, Pardo F, et al. Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer. J Gastrointest Oncol. 2014 Apr;5(2):148-153 | es_ES |
dc.identifier.issn | 2078-6891 | - |
dc.identifier.uri | https://hdl.handle.net/10171/36414 | - |
dc.description.abstract | Assess the surgical complications of primary tumor resection in stage IV colon cancer patients previously treated with neoadjuvant chemotherapy. METHODS: Between July 2001 and September 2010, 67 consecutive patients received preoperative chemotherapy. Clinical and surgical complications were obtained from the medical records. This study was retrospective in design. RESULTS: All patients were affected with liver metastasis, and 29.8% had metastasis in additional organs. Three different schemes of preoperative chemotherapy were employed, based on FOLFIRI, XELOXIRI or XELOX plus cetuximab. Eighteen patients (26.8%) reported some side effects to the chemotherapy, without contraindicating any intervention. All patients underwent colon surgery and within those, eight patients (11.9%), underwent liver surgery simultaneously. Median hospital admission was 8 [3-29] days. The perioperative complication rate was 16.2%, when the estimated physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) was 58.3%. There was not perioperative mortality, despite the mortality prediction for Portsmouth-POSSUM (P-POSSUM) being 5.07%. No differences were observed between the chemotherapy regimen (P=0.72) or the kind of the surgery-simple or combined (P=0.58). CONCLUSIONS: Neoadjuvant chemotherapy as a systemic treatment for stage IV colon cancer does not indicate surgery contraindication nor increases postoperative morbimortality by a significant amount. KEYWORDS: Stage IV colon cancer; neoajuvant chemotherapy; physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM); surgical morbidity | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Pioneer Bioscience Publishing Company | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Stage IV colon cancer | es_ES |
dc.subject | Neoajuvant chemotherapy | es_ES |
dc.subject | Physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) | es_ES |
dc.subject | Surgical morbidity | es_ES |
dc.title | Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.3978/j.issn.2078-6891.2014.015 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.